Are patients with alcohol-related fatty liver at increased risk of coronary heart disease?

Hepatic steatosis is defined when the deposition of triglyceride (TG) as lipid droplets in the cytoplasm of hepatocytes in more than 5% of hepatocytes. TG is a preferred storage nutrient as it provide greater caloric density (9 kcal/g) than do carbohydrates (4.5 kcal/g) or protein (4 kcal/g), and is insoluble in water, so they can accumulate to high levels with no adverse osmotic or colloidal effects on cells. TG is usually stockpiled in adipocytes, however, it accumulates in other cell types under certain circumstances. A common cause for hepatic steatosis is use of significant alcohol consumption. Fatty liver develops in about 90% of individuals who drink significant amount of alcohol. There are some other causes for hepatic fat accumulation, such as medication, inborn errors of metabolism (e.g., cholesterol ester storage disease), Reye’s syndrome, Wilson’s disease, lipodystrophy, abetalipoproteinemia, etc. Nonalcoholic fatty liver disease (NAFLD) is also common cause of hepatic steatosis, and is defined when there are no causes for secondary hepatic fat accumulation, such as significant alcohol consumption, use of steatogenic medication or hereditary disorders. In humans, fatty liver can have severe clinical consequences. If underlying causes for hepatic steatosis are not corrected (e.g., abstinence in case of alcoholic fatty liver, weight reduction in case of NAFLD), progression to hepatic fibrosis and liver cirrhosis may occur. Furthermore, fatty liver is not only limited to causing hepatic problems. It is well accepted that patients with NAFLD are at increased risk of complication related to metabolic disease, in particular, cardiovascular disease. In patients with NAFLD, insulin resistance is commonly found, and is considered as the common pathophysiological mechanism that explains metabolic derangement of the body, observed in NAFLD. However, whether NAFLD is a cause or consequence of insulin resistance remains unclear. If TG accumulation in hepatocytes causes insulin resistance in human, fatty liver itself, independent of causes for hepatic steatosis, will be associated with metabolic disease. So far, association between fatty liver and cardiovascular disease is extensively studied in patients with NAFLD, but not for fatty liver that is related to significant alcohol consumption. In this issue of the Clinical and Molecular Hepatology, Kim et al, assessed whether alcoholic fatty liver is associated with coronary heart disease risk. They analyzed the association between hepatic steatosis and coronary heart disease risk in 10,710 health check-up participants. Hepatic steatosis was diagnosed with ultrasonography, and individuals were divided into alcoholic fatty liver Are patients with alcohol-related fatty liver at increased risk of coronary heart disease?